Morning and evening administration of pantoprazole: A study to compare the effect on 24-hour intragastric pH

European Journal of Gastroenterology and Hepatology

Volumn 9, Issue 6, 1997, Pages 599-602

  Müssig, Stefan ^a   Witzel, Lothar ^b   Lühmann, Reinhold ^c   Schneider, Andreas ^c  

^a Byk Gulden ^*  (Germany)

^b NONE   (Germany)

^c ALTANA PHARMA AG   (Germany)

Author keywords

Acid related diseases; Intragastric pH; Pantoprazole

Indexed keywords

PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

EID: 0030919460     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199706000-00009     Document Type: Article

References (14)

1. +)-ATPase inhibitor. Biochem Pharmacol 1990, 39:1799-1806.
2. Simon B, Müller P, Marinis E, et al.: Effect of repeated oral administration of BY1023/SK&F96022 - a new substituted benzimidazole derivative - on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990, 4:373-379.
3. Müller P, Simon B, Khalil H, et al.: Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 1992, 30:771-775.
4. Londong W. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994, 9(suppl. 1):39-46.
5. Reill L, Erhardt F, Fischer R, et al.: Intragastric pH and serum gastrin after one week treatment with pantoprazole, ranitidine or placebo in man. Gastroenterology 1993, 104:A177.
6. Hartmann M, Bliesath H, Kuhn I, et al.: 24 h intragastric pH following oral intake of pantoprazole and omeprazole. Hellenic J Gastroenterol 1992, 5(suppl.):112.
7. Judmaier G, Koelz HR and Pantoprazole Duodenal Ulcer Study Group: Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Aliment Pharmacol Ther 1994, 8:81-86.
8. Koop H, Schepp W, Dammann HG, et al.: Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. J Clin Gastroenterol 1995, 20:192-195.
9. Witzel L, Gütz H, Hüttemann W, et al.: Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995, 9:19-24.
10. +-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole. Biochem Pharmacol 1991, 42:347-355.
11. McTavish D, Buckley MM-T, Heel RC: Omeprazole: an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991, 42:138-170.
12. Mössner J, Hölscher AH, Herz R, et al.: A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995, 9:321-326.
13. Prichard PJ, Yeomans ND, Mihaly GW, et al.: Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985, 88:64-69.
14. Chiverton SG, Howden CW, Burget DW, et al.: Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 1992, 6:103-111.